Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Mallinckrodt
Moodys
AstraZeneca
Boehringer Ingelheim

Last Updated: May 27, 2022

Omadacycline tosylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for omadacycline tosylate and what is the scope of freedom to operate?

Omadacycline tosylate is the generic ingredient in one branded drug marketed by Paratek Pharms Inc and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Omadacycline tosylate has two hundred and thirty-four patent family members in forty countries.

Summary for omadacycline tosylate
International Patents:234
US Patents:10
Tradenames:1
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 12
DailyMed Link:omadacycline tosylate at DailyMed

US Patents and Regulatory Information for omadacycline tosylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for omadacycline tosylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 See Plans and Pricing See Plans and Pricing
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for omadacycline tosylate

Country Patent Number Title Estimated Expiration
European Patent Office 2262754 9-[(2,2-DIMETHYL-PROPYL AMINO)-METHYL]-MINOCYCLINE DESTINE AU TRAITEMENT DU SDRM (MRSA) (9-[(2,2-DIMETHYL-PROPYL AMINO)-METHYL]-MINOCYCLINE FOR THE TREATMENT OF MRSA) See Plans and Pricing
Japan 6129235 See Plans and Pricing
Mexico 2010010585 FORMULACIONES ORALES E INYECTABLES DE COMPUESTOS DE TETRACICLINA. (ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS.) See Plans and Pricing
Taiwan I299038 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Dow
Johnson and Johnson
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.